How do we separate proven findings from marketing hype?
Depression research is one of medicine's largest evidence bases — and one of its most contested storytelling battlegrounds. The field teaches the sharpest lesson in this library about effect-size honesty: the gap between 'statistically significant' and 'life-changing,' the publication-bias corrections that shrank some drug effects, and the adjunct trials whose modest, real effects the supplement aisle inflates. We interpret the literature in the context of APA and NICE guidance.
No field teaches effect-size literacy better — the lessons here apply to every page in this library:
From Hippocratic melancholia through Kraepelin's classifications — the condition described for millennia before it was treatable.
Iproniazid (a tuberculosis drug) and later imipramine lift mood as side effects — the monoamine era begins by accident.
Prozac arrives — better-tolerated antidepressants, mass treatment, and the simple-chemical-imbalance marketing the field would spend decades correcting.
The BDNF/neuroplasticity model and the inflammation hypothesis widen the science — depression as network state, not serotonin level.
The first RCT of dietary intervention as depression treatment: Mediterranean-pattern dietitian support significantly improves outcomes.
The glutamate-pathway nasal spray approved for treatment-resistant depression — the first genuinely new antidepressant mechanism in decades, proof the field still moves.
POPULATION · 67 adults with moderate-to-severe major depression
FINDING · Dietitian-delivered Mediterranean-style dietary support produced significantly greater improvement than matched social support over 12 weeks — remission roughly a third higher, with dose-response by adherence.
LIMITATION · Modest sample; unblinded by design (participants knew their group); the intervention was structured support, not just food — real-world solitary dieting is a different exposure.
POPULATION · Adult volunteers in early randomized trials of the strain pair
FINDING · The L. helveticus R0052 + B. longum R0175 combination improved measures of mood and stress response versus placebo in early human trials.
LIMITATION · Small samples, healthy-volunteer populations more than clinical depression, early methodology — the honest grade is 'research direction,' a shelf presence away from proof.
POPULATION · Cohorts with paired vitamin D levels and depression measures
FINDING · Low vitamin D consistently associates with depression — and correction trials in deficient patients show modest mood benefit, concentrated where deficiency existed.
LIMITATION · Association is confounded (illness reduces outdoor activity — reverse causality); benefit in replete patients is essentially absent — the claim belongs to deficiency correction, not supplementation at large.